Plus therapeutics presents positive data from ongoing respect™ clinical trials at the annual conference on cns clinical trials and brain metastases

Austin, texas, aug. 13, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, yesterday presented positive data from two ongoing clinical trials of its lead investigational drug, rhenium-186 nanoliposome (186rnl), in the treatment of recurrent glioblastoma (gbm) and leptomeningeal metastases (lm) at the 2022 annual conference on cns clinical trials and brain metastases. the conference is co-sponsored by the society for neuro-oncology (sno) and the american society of clinical oncology (asco) and is being held august 12-13, 2022 in toronto, canada.
PSTV Ratings Summary
PSTV Quant Ranking